On October 14, 2026, FDA’s Enforcement Report published Class II classifications for voluntary recalls of compounded tirzepatide and semaglutide injectables from two pharmacies. The agency dated the classifications October 8. The firms had already started the recalls in September.

This is a sterility-assurance story, not a new consumer press release, and not a ban on compounding GLP-1 drugs. The reports do not say laboratory testing found microbes in these lots.

TL;DR

  • What: FDA classified Class II recalls for lack of assurance of sterility on compounded tirzepatide and semaglutide injectables, plus related lines.
  • Who: Carolina Infusion, LLC in Ridgeland, SC (listed by FDA as a 503A facility) and Apothecary Pharma LLC in Cary, NC (listed as a 503B outsourcing facility).
  • When: Firms initiated on September 10 (Carolina Infusion) and September 24 (Apothecary Pharma). FDA classified on October 8 and posted the Enforcement Report dated October 14.
  • How big: Patient-specific syringes at Carolina Infusion, and 22 vials of tirzepatide 18 mg/mL (4 mL) at Apothecary Pharma, plus 1 vial of NAD+. Status in the dataset: Ongoing.
  • The caveat: Class II means temporary or reversible harm is possible, or serious harm is remote. It is not a Class I death-risk recall, not an FDA drug ban, and not proof the lots were contaminated.

What did FDA actually post?

FDA’s Enforcement Report is the official running log of recalls the agency monitors. As FDA explains on that page, firms often start a recall and may warn customers before FDA finishes its hazard assessment. The October 14 posting is the classification, not proof that something new happened that week.

Both actions are labeled Voluntary: Firm initiated. Distribution is nationwide in the United States. As of the October 14 dataset, both events are Ongoing.

Carolina Infusion used email as the initial firm notification. Products were single-use, patient-specific syringes. Peptide lines in event 99867 include tirzepatide, tirzepatide with cyanocobalamin (vitamin B12), semaglutide, semaglutide with B12, and sermorelin acetate 1 mg/mL.

Apothecary Pharma used a letter. Event 99952 covers Tirzepatide Injection, 18 mg/mL, 4 mL sterile multi-dose vial, NDC 85091-001-18, quantity 22 vials, and a separate NAD+ 200 mg/mL 6 mL vial (1 vial). Lots for the tirzepatide vials run from AP-202622 through AP-202644, with beyond-use dates from October 7 through November 26, 2026.

The same Carolina Infusion event also covers non-peptide tri-mix and quad-mix injectables. Those lines are outside the peptide story, but they sit in the same sterility-assurance event.

If the 503A vs. 503B split is new, our explainer on the compounded peptides and the 503A/503B landscape in 2026 is the map. Plain-English terms live in the peptide glossary.

Which peptide products are in the classified recalls?

The table below is limited to the peptide lines in the October 14 Enforcement Report records. Quantities are what FDA recorded, not a patient count.

Firm Product (as listed) Quantity Recall no.
Carolina Infusion (503A) Tirzepatide 26 mg/mL injectable 5.6 mL, patient-specific syringes D-0017-2027
Carolina Infusion (503A) Semaglutide 3 mg/mL injectable 8 x 0.1 mL syringes D-0018-2027
Carolina Infusion (503A) Semaglutide/cyanocobalamin 3/2 mg/mL 57.0 mL, patient-specific syringes D-0019-2027
Carolina Infusion (503A) Sermorelin acetate 1 mg/mL injectable 15 mL, patient-specific syringes D-0020-2027
Carolina Infusion (503A) Semaglutide/cyanocobalamin 9/2 mg/mL 82.9 mL, patient-specific syringes D-0026-2027
Carolina Infusion (503A) Tirzepatide/cyanocobalamin 26/2 mg/mL 297 mL, patient-specific syringes D-0027-2027
Carolina Infusion (503A) Tirzepatide/cyanocobalamin 64/2 mg/mL 29.6 mL, patient-specific syringes D-0028-2027
Carolina Infusion (503A) Tirzepatide/cyanocobalamin 76/2 mg/mL 24.8 mL, patient-specific syringes D-0029-2027
Carolina Infusion (503A) Tirzepatide/cyanocobalamin 85/2 mg/mL 30.4 mL, patient-specific syringes D-0030-2027
Apothecary Pharma (503B) Tirzepatide injection 18 mg/mL, 4 mL vial 22 vials D-0036-2027
Apothecary Pharma (503B) NAD+ injection 200 mg/mL, 6 mL vial 1 vial D-0037-2027

The largest Carolina Infusion peptide line by volume is tirzepatide/cyanocobalamin 26/2 mg/mL at 297 mL. That is still a patient-specific syringe recall, not a warehouse-scale consumer product pull.

For how these two molecules compare as FDA-approved drugs, not as compounded copies, see our tirzepatide vs. semaglutide trial comparison.

What “lack of assurance of sterility” does, and does not, mean

FDA defines a Class II recall as a situation where use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.

These classifications would:

  • Flag specific lots and presentations for removal or correction because sterility was not assured.
  • Put the reason on the public Enforcement Report, including Carolina Infusion’s note on “bacteriostic water” (FDA’s spelling in the record) and processing equipment.
  • Sit alongside FDA’s broader compounding surveillance page, which already lists Carolina Infusion as a 503A facility and Apothecary Pharma as a 503B facility.

These classifications would NOT:

  • Prove the lots were contaminated. The recorded reason is lack of assurance, not a stated positive sterility-test failure.
  • Ban compounded tirzepatide, semaglutide, or sermorelin as a class.
  • Convert compounded copies into FDA-approved Mounjaro/Zepbound or Ozempic/Wegovy.
  • Tell an individual patient to stop or continue a prescribed product. That is a clinician call.

Carolina Infusion’s peptide entries specifically cite formulation with bacteriostatic water (the report’s “bacteriostic”) plus processing equipment. What that diluent is, and what it is not, is covered in our bacteriostatic water explainer. Apothecary Pharma’s entries say only lack of assurance of sterility, with no further mechanism in the Enforcement Report text.

FDA’s compounding-actions page also lists a Form 483 issued August 18, 2026 to Carolina Infusion. The same page lists a December 1, 2025 warning letter and a May 15, 2025 Form 483 for Apothecary Pharma.

A Form 483 is a list of inspectional observations, not a recall and not a final agency determination. The Enforcement Report does not say those older documents caused these September recalls.

Realistic timeline: classification lagged the firm start

Carolina Infusion dated initiation September 10, 2026. Apothecary Pharma dated initiation September 24, 2026. FDA’s center classification date for both is October 8, with the Enforcement Report date October 14.

That lag is normal. FDA says classification often comes after the firm supplies the information needed to judge public-health risk.

Readers who only watch consumer recall press releases can miss Enforcement Report rows entirely. FDA notes on the consumer recall page that not all recalls have press releases.

Lots and beyond-use dates are listed in the Enforcement Report entries. Some Carolina Infusion beyond-use dates were already in September, while some Apothecary Pharma tirzepatide dates run into late November 2026. Status was Ongoing in the October 14 dataset.

What it means for patients and practitioners

For patients, this is a lot-and-pharmacy check, not a reason to panic about every GLP-1. If you were dispensed compounded tirzepatide, semaglutide, sermorelin, or NAD+ from these firms, the practical step is to contact the prescriber and the pharmacy with the lot number on the label. Adverse events can be reported through FDA MedWatch.

For practitioners, the signal is sterility process control on compounded injectables, including GLP-1 combinations with B12. It is not a clinical efficacy finding, and it is not a verdict on branded products. If you are helping a patient find a licensed prescriber rather than a research vendor, start with our provider directory.

For the market, two unrelated firms landing Class II sterility-assurance recalls in the same Enforcement Report week is a reminder that compounding quality is lot-specific. Verification still matters more than a marketing claim. That is why we keep verified sources and COA pages separate from news.

Bottom line. FDA classified two voluntary, nationwide, Class II recalls of compounded tirzepatide and semaglutide injectables for lack of sterility assurance. That is a quality-process flag on named lots, not a contamination report, not a compounding ban, and not medical advice.

Not medical advice. This article is educational and informational only. Nothing here is a prescription, dosing recommendation, or instruction to start, stop, or switch a medication. Always consult a licensed healthcare provider.

We’ll update this story if FDA upgrades the classification, posts a consumer recall notice, or closes the events. Check the dateline above for the latest revision.